

Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ

Ref: FOI-052023-00053

Date: 2nd June 2023

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request

Could you please tell me how many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab Remicade
- Infliximab Biosimilar
- Ixekizumab

FOI/REF FOI-

- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

Response

In the 3 months, Feb23-Apr23, the following number of patients were treated by the Dermatology department (for any medical condition) with the listed biologic drugs:

| TreatmentNo. of PatientsAdalimumab - Humira7Adalimumab Biosimilar74Apremilast1Bimekizumab6Brodalumab1Certolizumab2Deucravacitinib0Dimethyl fumarate0Etanercept - Enbrel1Etanercept Biosimilar0Guselkumab21Infliximab - Remicade0Infliximab Biosimilar2Ixekizumab1Risankizumab13Secukinumab58Tildrakizumab10Ustekinumab16 | | • |
|--|-----------------------|-----------------|
| Adalimumab Biosimilar 74 Apremilast 1 Bimekizumab 6 Brodalumab 1 Certolizumab 2 Deucravacitinib 0 Dimethyl fumarate 0 Etanercept - Enbrel 1 Etanercept Biosimilar 0 Guselkumab 21 Infliximab - Remicade 0 Infliximab Biosimilar 2 Ixekizumab 1 Risankizumab 13 Secukinumab 58 Tildrakizumab 10 | Treatment | No. of Patients |
| Apremilast 1 Bimekizumab 6 Brodalumab 1 Certolizumab 2 Deucravacitinib 0 Dimethyl fumarate 0 Etanercept - Enbrel 1 Etanercept Biosimilar 0 Guselkumab 21 Infliximab - Remicade 0 Infliximab Biosimilar 2 Ixekizumab 1 Risankizumab 13 Secukinumab 58 Tildrakizumab 10 | Adalimumab - Humira | 7 |
| Bimekizumab 6 Brodalumab 1 Certolizumab 2 Deucravacitinib 0 Dimethyl fumarate 0 Etanercept - Enbrel 1 Etanercept Biosimilar 0 Guselkumab 21 Infliximab - Remicade 0 Infliximab Biosimilar 2 Ixekizumab 1 Risankizumab 13 Secukinumab 58 Tildrakizumab 10 | Adalimumab Biosimilar | 74 |
| Brodalumab 1 Certolizumab 2 Deucravacitinib 0 Dimethyl fumarate 0 Etanercept - Enbrel 1 Etanercept Biosimilar 0 Guselkumab 21 Infliximab - Remicade 0 Infliximab Biosimilar 2 Ixekizumab 1 Risankizumab 13 Secukinumab 58 Tildrakizumab 10 | Apremilast | 1 |
| Certolizumab2Deucravacitinib0Dimethyl fumarate0Etanercept - Enbrel1Etanercept Biosimilar0Guselkumab21Infliximab - Remicade0Infliximab Biosimilar2Ixekizumab1Risankizumab13Secukinumab58Tildrakizumab10 | Bimekizumab | 6 |
| Deucravacitinib0Dimethyl fumarate0Etanercept - Enbrel1Etanercept Biosimilar0Guselkumab21Infliximab - Remicade0Infliximab Biosimilar2Ixekizumab1Risankizumab13Secukinumab58Tildrakizumab10 | Brodalumab | 1 |
| Dimethyl fumarate 0 Etanercept - Enbrel 1 Etanercept Biosimilar 0 Guselkumab 21 Infliximab - Remicade 0 Infliximab Biosimilar 2 Ixekizumab 1 Risankizumab 13 Secukinumab 58 Tildrakizumab 10 | Certolizumab | 2 |
| Etanercept - Enbrel1Etanercept Biosimilar0Guselkumab21Infliximab - Remicade0Infliximab Biosimilar2Ixekizumab1Risankizumab13Secukinumab58Tildrakizumab10 | Deucravacitinib | 0 |
| Etanercept Biosimilar 0 Guselkumab 21 Infliximab - Remicade 0 Infliximab Biosimilar 2 Ixekizumab 1 Risankizumab 13 Secukinumab 58 Tildrakizumab 10 | Dimethyl fumarate | 0 |
| Guselkumab21Infliximab - Remicade0Infliximab Biosimilar2Ixekizumab1Risankizumab13Secukinumab58Tildrakizumab10 | Etanercept - Enbrel | 1 |
| Infliximab - Remicade 0 Infliximab Biosimilar 2 Ixekizumab 1 Risankizumab 13 Secukinumab 58 Tildrakizumab 10 | Etanercept Biosimilar | 0 |
| Infliximab Biosimilar 2 Ixekizumab 1 Risankizumab 13 Secukinumab 58 Tildrakizumab 10 | Guselkumab | 21 |
| Ixekizumab1Risankizumab13Secukinumab58Tildrakizumab10 | Infliximab - Remicade | 0 |
| Risankizumab 13 Secukinumab 58 Tildrakizumab 10 | Infliximab Biosimilar | 2 |
| Secukinumab 58 Tildrakizumab 10 | Ixekizumab | 1 |
| Tildrakizumab 10 | Risankizumab | 13 |
| | Secukinumab | 58 |
| Ustekinumab 16 | Tildrakizumab | 10 |
| | Ustekinumab | 16 |

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

FOI/REF FOI-

Information Governance Manager Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ

Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Tel: 0303 123 1113 www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust